March 10, 2022 Synthetic Biologics to Host Conference Call and Webcast to Discuss 2021 Year End Operational Highlights and Financial Results
February 8, 2022 Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA
January 26, 2022 Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022
December 14, 2021 Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors
November 3, 2021 Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET
October 26, 2021 Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021
October 21, 2021 Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase
October 6, 2021 Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
September 21, 2021 Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
